West London Mental Health NHS Trust

West London Mental Health NHS Trust Performance in Initiating Q1 18/19

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease.	No		132			01/05/2017	21/09/2017	04/10/2016	23/01/2018	31/01/2018	Please Select...	12/02/2018	E - Staff availability issues	Waiting for new PI to be appointed	NHS Provider
16/LO/1622	189449	Investigation of a New Satiety Inducing Diet for the Treatment of Obesity in the NHS	Yes	29/11/2017	6	119	125	24/04/2017	27/07/2017	26/09/2016	02/08/2017	02/08/2017	Please Select...	02/08/2017	J - Other	Issue of room availability for the clinics from which the study was recruiting.	NHS Provider
17/EE/0114	221275	A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)	Yes	01/01/2018	34	-9	25	07/12/2017	07/12/2017	12/06/2017	09/01/2018	10/01/2018	Please Select...	10/01/2018	D - Sponsor Delays H - Contracting delays	The first participant was recruited prior to site selection due to study design (feeder study) and contract delays.	Sponsor
16/SS/0115	206867	A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive	Yes	11/12/2017	20	26	46	20/10/2017	26/10/2017	25/08/2016	10/11/2017	15/11/2017	Please Select...	15/11/2017			Please Select...

		Impairment Due to Alzheimer's Disease (Prodromal AD).															
17/SC/0081	221195	A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease	Yes	16/11/2017	0	22	22	23/10/2017	25/10/2017	21/04/2017	25/10/2017	25/10/2017	Please Select...	25/10/2017			Please Select...
17/SC/0595	233484	A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis	No					05/02/2018	12/03/2018	12/02/2018			Please Select...		A - Permissions delayed/denied H - Contracting delays	Pharmacy support issues	NHS Provider
18/WM/0076	236872	REMEDY: Management of sexual dysfunction associated with antipsychotic drugs	No		28			14/05/2018	30/05/2018	08/05/2018	27/06/2018	27/06/2018	Please Select...	02/07/2018			Please Select...

West London Mental Health NHS Trust Performance in Delivery Q1 18/19

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
16/WS/0138	208282	A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (ACADIA)	Number Agreed	5	5	Date Agreed	02/04/2018	2	04/10/2017	2	Withdrawn By Sponsor	
17/SC/0081	221195	"A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease"	Number Agreed	2	2	Date Agreed	01/02/2020	2	28/11/2017	2	Withdrawn By Sponsor	The Sponsor decided to stop recruitment early, because there was a potential overlap with another study of theirs.
16/SS/0115	206867	A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).	Number Agreed	3	3	Date Agreed	31/12/2018	1	16/02/2018	1	Withdrawn By Sponsor	Following a futility analysis the data monitoring committee (Sponsor) decided to close the study early.